{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:58Z","timestamp":1793159158076,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancers have become the second leading cause of death worldwide, following cardiovascular diseases.Traditional anti- cancer strategies, including radiotherapy chemotherapy, surgery, and targeted therapies, have been widely used but are often reassessed due to their significant side effects and relatively low cure rate. Recently, the development of novel formulations for anti-tumor drugs has gained considerable attention, marking a pivotal step forward in cancer treatment advancements. These innovative formulations aim to enhance the therapeutic efficacy of anti-tumor drugs by employing advanced drug formulation technologies and delivery systems. In particular, nano-drug delivery systems (NDDS) have emerged as a promising approach to improve drug targeting, reduce side effects, and overcome drug resistance. This review highlights recent progress in NDDS for anti-tumor drug development and explores the future prospects of these advanced formulations in improving cancer treatment outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2024.1507958","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T01:18:30Z","timestamp":1734311910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Research progress of novel anti-tumor drug formulations"],"prefix":"10.3389","volume":"14","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunYan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengNa","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FanBo","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031532","article-title":"Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy","volume":"23","author":"Dasari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1038\/s41598-021-84770-0","article-title":"APTES monolayer coverage on self-assembled magnetic nanospheres for controlled release of anticancer drug Nintedanib","volume":"11","author":"Karade","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c21-00994","article-title":"Characterization of novel paclitaxel nanoparticles prepared by laser irradiation","volume":"70","author":"Suzuki","year":"2022","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1041073","article-title":"Activation of cancer immunotherapy by nanomedicine","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2103836","DOI":"10.1002\/advs.202103836","article-title":"Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy","volume":"9","author":"Peng","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-021-01569-7","article-title":"Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen [Management of chemotherapy side effects and their long-term sequelae","volume":"60","author":"Zraik","year":"2021","journal-title":"Urologe A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2094498","article-title":"Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610694","article-title":"On-target side effects of targeted therapeutics of cancer","volume":"28","author":"T\u00edm\u00e1r","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int J Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17404","DOI":"10.1038\/s41598-021-97081-1","article-title":"A pH-sensitive nanocarrier based on BSA-stabilized graphene-chitosan nanocomposite for sustained and prolonged release of anticancer agents","volume":"11","author":"Gooneh-Farahani","year":"2021","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr00032b","article-title":"Self-assembled nanomedicine combining a berberine derivative and doxorubicin for enhanced antitumor and antimetastatic efficacy via mitochondrial pathways","volume":"13","author":"Lin","year":"2021","journal-title":"Nanoscale"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111914","article-title":"Progress in the study of D-\u03b1-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance","volume":"205","author":"Yan","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12645-023-00190-x","article-title":"Monocytes reprogrammed by tumor microparticle vaccine inhibit tumorigenesis and tumor development","volume":"14","author":"Sun","year":"2023","journal-title":"Cancer Nanotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1038\/s41467-023-40270-5","article-title":"Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213993","article-title":"Tumor-derived exosomes and their role in breast cancer metastasis","volume":"23","author":"Huang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911789","article-title":"Hypoxia-regulated tumor-derived exosomes and tumor progression: A focus on immune evasion","volume":"23","author":"Shao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","article-title":"Emerging role of exosomes in cancer progression and tumor microenvironment remodeling","volume":"15","author":"Paskeh","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s13770-022-00430-y","article-title":"Nanozyme-based enhanced cancer immunotherapy","volume":"19","author":"Phan","year":"2022","journal-title":"Tissue Eng Regener Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00449-w","article-title":"Advances of mRNA vaccine in tumor: a maze of opportunities and challenges","volume":"11","author":"Yuan","year":"2023","journal-title":"biomark Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13111505","article-title":"Cytokine gene vaccine therapy for treatment of a brain tumor","volume":"13","author":"Lichtor","year":"2023","journal-title":"Brain Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120636","article-title":"Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy","volume":"269","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"B30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.actbio.2023.07.018","article-title":"Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer","volume":"168","author":"Wang","year":"2023","journal-title":"Acta Biomater"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c01610","article-title":"Acidity-actuated polymer\/calcium phosphate hybrid nanomotor (PCaPmotor) for penetrating drug delivery and synergistic anticancer immunotherapy","volume":"24","author":"Xu","year":"2024","journal-title":"Nano Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214245","article-title":"Bacteriophage-mediated cancer gene therapy","volume":"23","author":"Petrov","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051498","article-title":"Initial steps for the development of a phage-mediated gene replacement therapy using CRISPR-cas9 technology","volume":"9","author":"Yang Zhou","year":"2020","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.04.010","article-title":"Delivery of CRISPR\/Cas systems for cancer gene therapy and immunotherapy","volume":"168","author":"Song","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR-Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.873369","article-title":"Research progress on gene editing based on nano-drug delivery vectors for tumor therapy","volume":"10","author":"Xi","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122134","article-title":"Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation","volume":"299","author":"Huang","year":"2023","journal-title":"Biomaterials"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.03.001","article-title":"Cation-free siRNA-cored nanocapsules for tumor-targeted RNAi therapy","volume":"161","author":"Huang","year":"2023","journal-title":"Acta Biomater"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.10.030","article-title":"A polymer calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy","volume":"340","author":"Huang","year":"2021","journal-title":"J Control Release"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.01.012","article-title":"RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy","volume":"342","author":"Yoon","year":"2022","journal-title":"J Control Release"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.012","article-title":"Optimal delivery of RNA interference by viral vectors for cancer therapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-based therapeutics: delivering on the promise","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-021-01338-2","article-title":"RNA-based therapies: A cog in the wheel of lung cancer defense","volume":"20","author":"Khan","year":"2021","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168875","article-title":"Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets","volume":"23","author":"Barresi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26030701","article-title":"Recent advances in the development of exogenous dsRNA for the induction of RNA interference in cancer therapy","volume":"26","author":"Golubeva","year":"2021","journal-title":"Molecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-021-01085-y","article-title":"Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer","volume":"19","author":"Zhang","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e2100350","DOI":"10.1002\/adhm.202100350","article-title":"Innovations in biomaterial design toward successful RNA interference therapy for cancer treatment","volume":"10","author":"Ward","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S88381","article-title":"Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery","author":"Joo","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cssc.202000455","article-title":"Research progress in lignin-based slow\/controlled release fertilizer","volume":"13","author":"Chen","year":"2020","journal-title":"ChemSusChem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/med.21971","article-title":"(Nano)platforms in breast cancer therapy: Drug\/gene delivery, advanced nanocarriers and immunotherapy","volume":"43","author":"Ashrafizadeh","year":"2023","journal-title":"Med Res Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/marc.201400171","article-title":"Light and pH dual-degradable triblock copolymer micelles for controlled intracellular drug release","volume":"35","author":"Jin","year":"2014","journal-title":"Macromol Rapid Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.2147\/IJN.S379200","article-title":"ROS-generating poly(Ethylene glycol)-conjugated fe3O4 nanoparticles as cancer-targeting sustained release carrier of doxorubicin","volume":"17","author":"Adilakshmi","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.3c07379","article-title":"Cancer-erythrocyte membrane-mimicking fe3O4 nanoparticles and DHJS for ferroptosis\/immunotherapy synergism in tumors","volume":"15","author":"Yu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","article-title":"Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy","volume":"17","author":"Oroojalian","year":"2021","journal-title":"Small"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.05.028","article-title":"Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapy","volume":"112","author":"Chen","year":"2020","journal-title":"Acta Biomater"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c01534","article-title":"Biomimetic ghost nanomedicine-based optotheranostics for cancer","volume":"24","author":"Prasad","year":"2024","journal-title":"Nano Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2023.101648","article-title":"Bioinspired and biomimetic cancer-cell-derived membrane nanovesicles for preclinical tumor-targeted nanotheranostics","volume":"4","author":"Prasad","year":"2023","journal-title":"Cell Rep Phys Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2018.08.054","article-title":"Plasmonic carbon nanohybrids for repetitive and highly localized photothermal cancer therapy","volume":"172","author":"Chauhan","year":"2018","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.6b04695","article-title":"Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1515\/nanoph-2021-0205","article-title":"Nanoengineered photoactive theranostic agents for cancer","volume":"10","author":"Jain","year":"2021","journal-title":"Nanophotonics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1507958\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T01:18:32Z","timestamp":1734311912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1507958\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":63,"alternative-id":["10.3389\/fonc.2024.1507958"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1507958","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1507958"}}